XML 89 R152.htm IDEA: XBRL DOCUMENT
v3.20.1

Non-Controlling Interests - Movement (Details) - EUR (€) € in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | € 4,696,604 | € 3,633,965 | € 3,727,978
Profit/(loss) for the year | 648,644 | 594,406 | 661,314
Balance at end of the year | 6,845,768 | 4,696,604 | 3,633,965
Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 471,050 | 4,886 | 6,497
Profit/(loss) for the year | 23,498 | (2,236) | (1,386)
Additions |  | (2,236) |
Additions | 1,534,045 |  |
Disposals | (9) | (914) |
Business combinations/ Additions to consolidated Group |  | 469,881 |
Capital increases | 6,642 |  |
Translation differences | 11,921 | (567) |
Balance at end of the year | 2,023,649 | 471,050 | 4,886
Grifols (Thailand) Ltd | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 3,935 | 3,579 |
Profit/(loss) for the year | 193 | 193 |
Disposals |  | (43) |
Translation differences | 421 | 206 |
Balance at end of the year | 4,549 | 3,935 | 3,579
Grifols Malaysia Sdn Bhd | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 1,735 | 1,372 |
Profit/(loss) for the year | 380 | 326 |
Translation differences | 56 | 37 |
Balance at end of the year | 2,171 | 1,735 | 1,372
Araclon Biotech, S.A | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | (3,488) | (1,477) |
Profit/(loss) for the year | (1,975) | (2,011) |
Capital increases | 5,892 |  |
Balance at end of the year | 429 | (3,488) | (1,477)
Progenika Biopharma, S.A. | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 9 | 880 |
Profit/(loss) for the year | 0 |  |
Disposals | (9) | (871) |
Balance at end of the year |  | 9 | 880
VCN Bioscience, S.L. | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 140 | 421 |
Profit/(loss) for the year | (292) | (281) |
Balance at end of the year | (152) | 140 | 421
Kiro Grifols , S.L. | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | (352) | 111 |
Profit/(loss) for the year | (374) | (463) |
Capital increases | 750 |  |
Balance at end of the year | 24 | (352) | € 111
Haema, AG | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 220,190 |  |
Profit/(loss) for the year | 5,881 |  |
Business combinations/ Additions to consolidated Group |  | 220,190 |
Balance at end of the year | 226,071 | 220,190 |
Biotest US Corporation | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Balance at beginning of the year | 248,881 |  |
Profit/(loss) for the year | 19,685 |  |
Business combinations/ Additions to consolidated Group |  | 249,691 |
Translation differences | 11,444 | (810) |
Balance at end of the year | 280,010 | € 248,881 |
Grifols Diagnostic Solutions, Inc. | Non-controlling interests |  |  |
Disclosure of subsidiaries [line items] |  |  |
Additions | 1,510,547 |  |
Balance at end of the year | € 1,510,547 |  |

X
- Definition The total additions to non-controlling interest including profit/loss for the period and changes in ownership interest. + References No definition available. + Details
Name: | grfs_AdditionsToNonControllingInterestTotal
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in additions to equity resulting from non-controlling interest. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseAdditionsToNonControllingInterest
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) through business combinations and additions to consolidated group. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseThroughBusinessCombinationsAndAdditionsToConsolidatedGroupEquity
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The (increase) decrease in equity resulting from disposals. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseThroughDisposalsEquity
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Translation differences and other changes. + References No definition available. + Details
Name: | grfs_TranslationDifferencesAndOtherChanges
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of residual interest in the assets of the entity after deducting all its liabilities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2019-01-01 -Paragraph 24 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_24_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2019-01-01 -Paragraph 32 -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_32_a_i&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2019-01-01 -Paragraph 93 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2019-en-r&anchor=para_93_a&doctype=Standard -URIDate 2019-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2019-01-01 -Paragraph 93 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2019-en-r&anchor=para_93_b&doctype=Standard -URIDate 2019-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2019-01-01 -Paragraph 93 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2019-en-r&anchor=para_93_e&doctype=Standard -URIDate 2019-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_55&doctype=Standard -URIDate 2019-03-27 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 78 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_78_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_Equity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 106 -Subparagraph d -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_iii&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2019-01-01 -Paragraph 18 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2019-01-01 -Paragraph 24 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_24_b&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2019-01-01 -Paragraph 32 -Subparagraph a -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_32_a_ii&doctype=Standard -URIDate 2019-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 28 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_b&doctype=Standard -URIDate 2019-03-27 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Note Effective on first application of IFRS 9 -Name IFRS -Number 4 -IssueDate 2019-01-01 -Paragraph 39L -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2019-en-b&anchor=para_39L_e&doctype=Standard -URIDate 2019-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 23 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23&doctype=Standard -URIDate 2019-03-27 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B10 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 106 -Subparagraph d -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_i&doctype=Standard -URIDate 2019-03-27 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Note Effective 2021-01-01 -Name IFRS -Number 17 -IssueDate 2019-01-01 -Paragraph 113 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2019-en-r&anchor=para_113_b&doctype=Standard -URIDate 2019-03-27 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 81A -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_81A_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProfitLoss
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsThailandLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsMalaysiaSdnBhdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_AraclonBiotechS.A.MemberRaclonBiotechS.a.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_ProgenikaBiopharmaSaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_VcnBioscienceSlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_KiroGrifolsLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_HaemaAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_BiotestUsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsDiagnosticSolutionsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |